Regeneron declines a higher bid for 23andMe (REGN:NASDAQ) - Seeking Alpha
11 hours ago • Google News
Regeneron Pharmaceuticals Inc (REGN)
US$ 596.85-1.29%
Price Chart
Key Statistics
Market Cap
$ 57.14B
P/E Ratio
13.46
Revenue (TTM)
$ 14.09B
Volume
857.99K
52W High
$ 1207.86
52W Low
$ 476.49
Dividend Yield
0.67%
Beta
0.31
Technicals
50-Day MA
561.947
200-Day MA
754.5039
52 Week High
1207.8611
52 Week Low
476.49
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Employees
15158
Headquarters
Tarrytown, NY
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Latest News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
22.33
Percentile: 26.82
Environmental Risk Score
1.51
Percentile: 2
Social Risk Score
13.94
Percentile: 2
Governance Risk Score
5.88
Percentile: 2
Controversy Level
ESG data provided by Sustainalytics, Inc.
REGN
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg